Author

H.- H. Hoffmann

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Microbiology· 3 Immunology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 5 Research Focus:host-pathogen & immune response· 4 Approach:genetic perturbation / CRISPR· 3 Research Focus:cell type annotation· 2 Approach:experimental assay· 2 Assay:proteomics· 2 Research Focus:clustering· 1 Research Focus:drug response / drug discovery· 1

Frequent Co-Authors

C. M. Rice· 5 shared A. F. Stenzel· 3 shared A. Peace· 3 shared A. W. Ashbrook· 3 shared E. Michailidis· 3 shared F. J. Sanchez-Rivera· 3 shared I. Ricardo-Lax· 3 shared J. Le Pen· 3 shared

Activity by Year

2020-2024 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

5 shared papersMicrobiology

C. M. Rice

Mutual co-authors in cluster

Author profile →

5 papers

Recent·Most cited

A genome-wide arrayed CRISPR screen identifies PLSCR1 as an intrinsic barrier to SARS-CoV-2 entry that recent virus variants have evolved to resist

J. Le Pen, G. Paniccia, V. Kinast, M. Moncada-Velez, A. W. Ashbrook, M. Bauer, H.- H. Hoffmann, A. Pinharanda, I. Ricardo-Lax, A. F. Stenzel, E. A. Rosado-Olivieri, K. H. Dinnon, W. C. Doyle, C. A. Freije, S.-H. Hong, , C. M. Rice

The paper identifies PLSCR1 as a host factor restricting SARS-CoV-2 entry, which recent variants have evolved to bypass, through a CRISPR screen and integration of genetic studies.

bioRxiv · Feb 16, 2024Immunology

Human anti-ACE2 monoclonal antibodies as pan-sarbecovirus prophylactic agents

F. Zhang, J. Jenkins, R. V. H. de Carvalho, S. Nakandakari-Higa, T. Chen, M. E. Abernathy, E. Nyakatura, D. Andrew, I. V. Lebedeva, I. C. Lorenz, H.- H. Hoffmann, C. M. Rice, G. D. Victora, C. O. Barnes, T. Hatziioannou, P. D. Bieniasz

The paper develops human monoclonal antibodies targeting the ACE2 receptor to block infection by SARS-CoV-2 and related sarbecoviruses, showing broad efficacy against variants and no adverse effects on ACE2 function.

bioRxiv · Aug 24, 2022 · PreprintMicrobiology

Naturally enhanced neutralizing breadth to SARS-CoV-2 after one year

Z. Wang, F. Muecksch, D. Schaefer-Babajew, S. Finkin, C. Viant, C. Gaebler, H.- H. Hoffmann, C. O. Barnes, M. Cipolla, V. Ramos, T. Y. Oliveira, A. Cho, F. Schmidt, J. D. Silva, E. Bednarski, , M. C. Nussenzweig

This study shows that convalescent individuals with or without vaccination maintain neutralizing activity and memory B cells against SARS-CoV-2 for up to one year, with vaccination enhancing breadth and potency against variants.

bioRxiv · May 7, 2021Immunology

Genome-scale identification of SARS-CoV-2 and pan-coronavirus host factor networks

W. M. Schneider, J. M. Luna, H.- H. Hoffmann, F. J. Sanchez-Rivera, A. A. Leal, A. W. Ashbrook, J. Le Pen, E. Michailidis, I. Ricardo-Lax, A. Peace, A. F. Stenzel, S. W. Lowe, M. R. MacDonald, C. M. Rice, J. T. Poirier

The paper identifies host factors required for SARS-CoV-2 and three seasonal coronaviruses using CRISPR screens, revealing shared and virus-specific dependencies.

bioRxiv · Oct 7, 2020Microbiology

Functional interrogation of a SARS-CoV-2 host protein interactome identifies unique and shared coronavirus host factors

H.- H. Hoffmann, W. M. Schneider, F. J. Sanchez-Rivera, J. M. Luna, A. W. Ashbrook, Y. M. Soto-Feliciano, A. A. Leal, J. Le Pen, I. Ricardo-Lax, E. Michailidis, Y. Hao, A. F. Stenzel, A. Peace, C. D. Allis, S. W. Lowe, , C. M. Rice

The paper identifies host factors critical for SARS-CoV-2 and related coronaviruses using CRISPR screens, revealing both shared and unique factors across different viruses and temperatures.

bioRxiv · Sep 11, 2020Microbiology